Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NLTX

NLTX - Neoleukin Therapeutics Inc Stock Price, Fair Value and News

$15.10 
Market Closed

Price Targets

NLTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NLTX Price Action

NLTX RSI Chart

NLTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NLTX Valuation

Market Cap

213.1M

Price/Earnings (Trailing)

-2.5

Price/Sales (Trailing)

230.42

EV/EBITDA

-4.58

Price/Free Cashflow

-2.72

NLTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

NLTX Fundamentals

NLTX Revenue

Revenue (TTM)

925.0K

NLTX Earnings

Earnings (TTM)

-85.1M

Earnings Growth (Yr)

-3.64%

Earnings Growth (Qtr)

4.83%

NLTX Profitability

EBT Margin

-3683.68%

Return on Equity

-32.06%

Return on Assets

-29.58%

Free Cashflow Yield

-36.77%

NLTX Investor Care

Shares Dilution (1Y)

4.28%

Diluted EPS (TTM)

-4.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024017.0M8.9M925.0K
201800025.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Neoleukin Therapeutics Inc

NLTX
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEneoleukin.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Neoleukin Therapeutics Inc Frequently Asked Questions

NLTX is the stock ticker symbol of Neoleukin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Oct 31 2025, market cap of Neoleukin Therapeutics Inc is 213.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NLTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether NLTX is over valued or under valued. Whether Neoleukin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Neoleukin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NLTX.

As of Fri Oct 31 2025, NLTX's PE ratio (Price to Earnings) is -2.5 and Price to Sales (PS) ratio is 230.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NLTX PE ratio will change depending on the future growth rate expectations of investors.